Characteristics | Baseline (2006) | Follow-up (2012) |
---|---|---|
General characteristics | Â | Â |
  Age (years) | 61 (53 to 67) | 67 (59 to 73) |
  Female, n (%) | 155 (77) | 155 (77) |
  Body mass index (kg/m2) | 27 (24 to 30) | 28 (24 to 32) |
Disease characteristics | Â | Â |
  Age at RA onset (years) | 46 ± 13 | – |
  Disease duration (years) | 10 (4 to 18) | 16 (11 to 25) |
  Rheumatoid factor-positive, n (%) | 148 (74) | 148 (74) |
  Anti-CCP autoantibody-positive, n (%) | 123 (61) | 123 (61) |
  DAS28 score | 4.0 (3.1 to 4.8) | 3.1 (2.5 to 4.0) |
  C-reactive protein (mg/L) | 7.5 (4.3 to 16) | 3 (2.9 to 8.5) |
  Erythrocyte sedimentation rate (mm/h) | 17 (8 to 30) | 12 (5 to 23) |
  HAQ | 1.3 ± 0.9 | 1.6 ± 0.9 |
  Extraarticular manifestations, n (%)b | 147 (73) | – |
Cardiovascular disease risk factors | Â | Â |
  Hypertension, n (%) | 132 (66) | 130 (65) |
  Dyslipidaemia, n (%) | 115 (57) | 158 (79) |
  Insulin resistance, n (%) | 65 (32) | 53 (26) |
  Diabetes, n (%) | 7 (4) | 21 (10) |
  Current smokers | 33 (16) | 23 (11) |
Global cardiovascular disease riskc | Â | Â |
  Framingham risk score (%) | 4.6 ± 5.3 | 9.2 ± 6.3 |
  Reynolds risk score (%) | 6.3 ± 6.4 | 9.6 ± 8.3 |
RA medications | Â | Â |
  Methotrexate, n (%) | 128 (64) | 122 (61) |
  Hydroxychloroquine, n (%) | 36 (18) | 50 (25) |
  Prednisolone, n (%) | 58 (29) | 51 (25) |
  Prednisolone dose (mg) | 6 ± 3 | 7 ± 8 |
  NSAIDs, n (%) | 47 (23) | 26 (13) |
  Cyclooxygenase 2 inhibitors, n (%) | 14 (7) | 5 (2.5) |
  Anti-TNFα therapy, n (%) | 20 (10) | 57 (28) |
  Tociluzimab, n (%) | – | 3 (1.5) |
Cardiovascular medications | Â | Â |
  Antihypertensives, n (%) | 81 (40) | 79 (39) |
  Antihypercholesterolaemics, n (%) | 33 (16) | 74 (37) |
  β-blockers, n (%) | 32 (16) | 22 (11) |
  Calcium channel blockers, n (%) | 26 (13) | 27 (13) |